PL
Insider
Perceptive Advisors Llc
DirectorPerceptive Advisors Llc (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (1 purchase, 1 sale), most often in ACRV. Across 1 priced purchase filing, the average 21-session return was -9.7% from execution and -10.6% from disclosure (delay-adjusted; derived). The largest single filing was $7.5M of IMTX (863,060 sh × $8.69, as filed), executed Aug 26. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-9.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-10.6%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$7.5M
shares × price, as filed
Last traded
Aug 26
Filed Aug 27
Median ADV $4.4M across their filed names
Open performance→Volume by month
Buys $9.4M
Sells $3.8M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Not on file
1 filing
Sector per market data · by filing · past 12 months
Most traded names
ACRV
ACRV
0 buys · 2 sells
2 filings
IMTXRecent filings
IMTXPURCHASE
Immatics N.V.
View filing →
$7.5M863,060 sh × $8.69
Exec Aug 26
Filed Aug 27 · 4:00 PM ET LYRASALE Lyra Therapeutics, Inc. View filing → –
28,597 sh · price not plausible
Exec Nov 13 2025
Filed Nov 13 2025 · 5:30 PM ET OBIOPURCHASE Orchestra BioMed Holdings, Inc. View filing → $1.9M
700,000 sh × $2.75
Exec Aug 1 2025
Filed Aug 5 2025 · 10:46 AM ET ACRVSALE Acrivon Therapeutics, Inc. View filing → $1.0M
736,767 sh across 2 lots
Exec Apr 30 2025
Filed May 1 2025 · 5:30 PM ET ACRVSALE Acrivon Therapeutics, Inc. View filing → $2.7M
1,519,952 sh across 3 lots
Exec Apr 25 2025
Filed Apr 29 2025 · 5:30 PM ET